Physician profile
Gotam Chand
NPI 1437318524
$542.39
in general payments reported to CMS, 2019-2025
12 companies · $226 in 2025
The $226 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21.17 · 2022: $19.31 · 2024: $276 · 2025: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $502.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $501.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $101.95 | 2024 | Xarelto |
| Merck Sharp & Dohme LLC | $77.92 | 2024-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.02 | 2024-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $68.50 | 2024 | |
| Boston Scientific Corporation | $49.46 | 2025 | Watchman Access System, General - Therapies |
| Janssen Pharmaceuticals, INC | $39.21 | 2022-2024 | Xarelto |
| Alexion Pharmaceuticals, INC. | $35.42 | 2025 | Ultomiris |
| Viatris Specialty LLC | $30.58 | 2025 | Yupelri |
| Pfizer INC. | $21.17 | 2019 | |
| Solventum Corporation | $18.99 | 2025 | V.A.C.Ulta |
| E.R. Squibb & Sons, L.L.C. | $15.89 | 2025 | Eliquis |
| Paratek Pharmaceuticals, INC. | $14.28 | 2025 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gotam Chand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.